EEG-based drug repurposing for rare CNS diseases
Official title: EEG Signature Analysis for Drug Repurposing for Rare Diseases
Funded at Psychogenics, INC. · NIH-11536936 · Data updated 2026-11-12
A new approach uses EEG brain signatures to find existing drugs that might help people with rare nervous-system disorders.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Psychogenics, INC. NIH-funded |
| Lab location | 1 site (Paramus, UNITED STATES) |
| Project start | August 5, 2024 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $924,001 |
| NIH project number | 4R44MH138151-03 |
| Project ID | NIH-11536936 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with rare CNS or psychiatric conditions that lack effective treatments, who may participate through future clinical testing or related biomarker studies.
✕Less likely to help
If a patient’s specific condition does not align with the modeled diseases or the drugs identified do not translate to humans, direct benefit may be limited.
What this research studies
This project aims to build an EEG-based drug repurposing platform using the eCube fast EEG system and animal models of rare diseases. Researchers will develop a Drug EEG Signature Analysis (DESA) algorithm to compare EEG patterns from disease models with reference drug signatures to generate repurposing hypotheses. The work blends behavioral neuroscience data with computational methods to streamline identifying potential therapies for conditions with few treatment options. If successful, the platform could speed up discovering new uses for already approved drugs, narrowing the gap between discovery and patient access.
Why it matters
Potential benefit: Could speed up identifying existing medications that might help patients with rare CNS disorders.
How similar studies have gone: Previous phenotypic drug repurposing efforts using EEG or behavioral signatures show promise but remain early in translation.
Where this research is happening
-
Psychogenics, INC.
Paramus, United States Active
Researchers
- Principal investigator: Leahy, Emer — Psychogenics, INC.
- Study coordinator: Leahy, Emer
Related research
Other NIH-funded projects on the same topics.
-
Liver pathobiology from rare liver diseases
A study at UCSF looks at why rare liver conditions cause liver damage, with the aim of finding new ways to diagnose and treat chronic liver disease.
-
Data Management and Coordinating Center support for Rare Diseases Research
A national rare diseases research program is funding a center to manage data and coordinate studies to help improve diagnosis, care, and potential treatments for children with rare conditions.
-
Ethics of Engaging Patient Groups in Drug Development for Rare Diseases
This grant asks how patient and family groups can ethically help shape rare-disease drug development from idea to market, with input from patients, families, doctors, and researchers.
-
Center for Polyamine Disorders group study of rare metabolic disorders
A research consortium is studying a group of rare metabolic disorders linked to polyamines and aims to understand symptoms, biomarkers, and disease progression to improve care.
-
Encore: speeding up finding new uses for existing drugs to help kids with rare diseases
A big NIH project will test thousands of existing medicines to see if any can help treat rare genetic diseases in children.
-
Advancing Craniosynostosis Care: Pilot/Feasibility Governance Core
A pilot and governance program to speed up practical ideas for better care for children with syndromic craniosynostosis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.